DeepMed Research

Nimotuzumab

Generic Name: Nimotuzumab

Drug Type: Biotech

CAS Number: 780758-10-3

Unique Ingredient Identifier: 6NS400BXKH

Indication: Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions: Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck

Clinical Trials

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer, Adult

Interventions: Drug: AG regimen
Drug: Nimotuzumab

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 48

Registration Number: NCT06938503

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Toripalimab
Drug: Nimotuzumab
Procedure: surgery

First Posted Date: 2025-04-06

Last Posted Date: 2025-05-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 70

Registration Number: NCT06912711

Locations: 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China

HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Drug: HRS-4642
Drug: Nimotuzumab

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-26

Lead Sponsor: West China Hospital

Target Recruit Count: 10

Registration Number: NCT06773130

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Phase 4

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Nimotuzumab
Drug: cis-platinum
Radiation: IMRT combine with cisplatin concurrent chemotherapy
Drug: painkiller

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 171

Registration Number: NCT06879691

Locations: 🇨🇳
Baotou Cancer Hospital, Baotou, Inner Mongolia, China

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Phase 3

Completed

Conditions: Cervical Squamous Cell Carcinoma
Persistent

Interventions: Drug: Nimotuzumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Placebo

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-17

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT06781073

Locations: 🇨🇳
Cancer Institute and Hospital , Chinese Academy of Medical Sciences, Beijing, China

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer, Adult

Interventions: Drug: Nimotuzumab
Drug: AG regimen
Drug: Placebo

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-17

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT06781086

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Phase 2

Active, not recruiting

Conditions: Uterine Cervical Neoplasms

Interventions: Drug: Nimotuzumab Injection

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT06771596

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Phase 2

Not yet recruiting

Conditions: Metastatic Pancreatic Carcinoma

Interventions: Drug: HRS-4642
Drug: Nimotuzumab
Drug: gemcitabine + nab-paclitaxel

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Zhejiang University

Target Recruit Count: 32

Registration Number: NCT06770452

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer Resectable

Interventions: Drug: Nimotuzumab
Drug: AG

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Zhejiang Provincial People's Hospital

Target Recruit Count: 57

Registration Number: NCT06722911

Locations: 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Nimotuzumab
Drug: Sintilimab
Drug: Paclitaxel-albumin
Drug: Cisplatin

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 112

Registration Number: NCT06718205

Locations: 🇨🇳
Feng Wang, Zhengzhou, Henan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy